UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
Teva Pharmaceutical Industries Ltd. ——————————————————————————————————— |
||||
| (Translation of registrant’s name into English) | ||||
| Israel ——————————————————————————————————— | ||||
| (Jurisdiction of incorporation or organization) | ||||
|
5 Basel Street, P.O. Box 3190 Petach Tikva 49131 Israel |
||||
|
——————————————————————————————————— (Address of principal executive office) |
||||
| Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
| Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
| Teva Pharmaceutical Industries Ltd. | ||
| Date: 10/03/2013 | By: |
Eyal Desheh |
| Name: | Eyal Desheh | |
| Title: | Chief Financial Officer | |
| Exhibit No. | Description | |
|
|
|
|
| 99.1 | TEVA ANOUNCES FAVORABLE RULING ON COPAXONE PATENT LITIGATION IN THE NETHERLANDS | |